ArticleMedicine2025
X-linked chronic granulomatous disease combined with disseminated nontuberculous mycobacteria and fungal infections: Diagnosis and treatment analysis.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
rationaleX-linked chronic granulomatous disease (X-CGD) is a rare genetic immunodeficiency, predominantly affecting males. It leads to defective neutrophil function and increased susceptibility to infections, particularly nontuberculous mycobacteria and fungi. Early diagnosis is challenging due to its nonspecific symptoms. PATIENT CONCERNS: A 1-year-5-month-old male presented with recurrent lymphadenopathy, erythematous and ulcerative skin lesions, and persistent fever. These symptoms, along with pulmonary involvement, raised concerns for infectious diseases, leading to a misdiagnosis of tuberculosis. DIAGNOSES: Genetic testing revealed a hemizygous mutation in the CYBB gene, confirming the diagnosis of X-CGD. Further investigations identified Mycobacterium gordonae and Candida parapsilosis as the causative pathogens.
interventionsThe patient received broad-spectrum antibiotics and antifungal therapy, including meropenem, clarithromycin, linezolid, and voriconazole. Immunomodulatory treatments, including intravenous immunoglobulin and interferon-γ, were initiated to support immune function. Hematopoietic stem cell transplantation was planned for long-term management. OUTCOMES: The patient showed significant improvement, with regression of cervical and pulmonary lesions. Ongoing recovery was observed, with plans for stem cell transplantation to achieve a potential cure. LESSONS: X-CGD should be suspected in cases with recurrent infections and unusual responses to treatment. Genetic testing is essential for confirmation, and early initiation of prophylactic and targeted therapies can improve outcomes. Awareness of atypical presentations is crucial for timely diagnosis and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.